Cargando…
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy
INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745798/ https://www.ncbi.nlm.nih.gov/pubmed/26471290 |
_version_ | 1782414720860422144 |
---|---|
author | Brady, Anna K. McNeill, Jonathan D. Judy, Brendan Bauml, Joshua Evans, Tracey L. Cohen, Roger B. Langer, Corey Vachani, Anil Aggarwal, Charu |
author_facet | Brady, Anna K. McNeill, Jonathan D. Judy, Brendan Bauml, Joshua Evans, Tracey L. Cohen, Roger B. Langer, Corey Vachani, Anil Aggarwal, Charu |
author_sort | Brady, Anna K. |
collection | PubMed |
description | INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 consecutive patients with stage IV NSCLC adenocarcinoma with known KRAS and EGFR MT status to determine the association of KRAS MT with survival. All patients were treated between January 1, 2008 and December 31, 2011 with standard platinum based chemotherapy at the University of Pennsylvania. Overall and progression free survival were analyzed using Kaplan-Meier and Cox proportional hazard methods. RESULTS: All patients in this series received platinum doublet chemotherapy, and 42 (45%) received bevacizumab. Overall survival and progression free survival for patients with KRAS MT was no worse than for patients with wild type KRAS. Median overall survival for patients with KRAS MT was 19 months (mo) vs. 15.6 mo for KRAS WT, p = 0.34, and progression-free survival was 6.2 mo in patients with KRAS MT vs. 7mo in patients with KRAS WT, p = 0.51. In multivariable analysis including age, race, gender, and ECOG PS, KRAS MT was not associated with overall survival (HR 1.12, 95% CI 0.58–2.16, p = 0.74) or progression free survival (HR 0.80, 95% CI 0.48–1.34, p = 41). Of note, receipt of bevacizumab was associated with improved overall survival only in KRAS WT patients (HR 0.34, p = 0.01). CONCLUSIONS: KRAS MT are not associated with inferior progression-free and overall survival in advanced NSCLC patients treated with standard first-line platinum-based chemotherapy. |
format | Online Article Text |
id | pubmed-4745798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47457982016-02-23 Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy Brady, Anna K. McNeill, Jonathan D. Judy, Brendan Bauml, Joshua Evans, Tracey L. Cohen, Roger B. Langer, Corey Vachani, Anil Aggarwal, Charu Oncotarget Clinical Research Paper INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 consecutive patients with stage IV NSCLC adenocarcinoma with known KRAS and EGFR MT status to determine the association of KRAS MT with survival. All patients were treated between January 1, 2008 and December 31, 2011 with standard platinum based chemotherapy at the University of Pennsylvania. Overall and progression free survival were analyzed using Kaplan-Meier and Cox proportional hazard methods. RESULTS: All patients in this series received platinum doublet chemotherapy, and 42 (45%) received bevacizumab. Overall survival and progression free survival for patients with KRAS MT was no worse than for patients with wild type KRAS. Median overall survival for patients with KRAS MT was 19 months (mo) vs. 15.6 mo for KRAS WT, p = 0.34, and progression-free survival was 6.2 mo in patients with KRAS MT vs. 7mo in patients with KRAS WT, p = 0.51. In multivariable analysis including age, race, gender, and ECOG PS, KRAS MT was not associated with overall survival (HR 1.12, 95% CI 0.58–2.16, p = 0.74) or progression free survival (HR 0.80, 95% CI 0.48–1.34, p = 41). Of note, receipt of bevacizumab was associated with improved overall survival only in KRAS WT patients (HR 0.34, p = 0.01). CONCLUSIONS: KRAS MT are not associated with inferior progression-free and overall survival in advanced NSCLC patients treated with standard first-line platinum-based chemotherapy. Impact Journals LLC 2015-09-03 /pmc/articles/PMC4745798/ /pubmed/26471290 Text en Copyright: © 2015 Brady et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Brady, Anna K. McNeill, Jonathan D. Judy, Brendan Bauml, Joshua Evans, Tracey L. Cohen, Roger B. Langer, Corey Vachani, Anil Aggarwal, Charu Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title_full | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title_fullStr | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title_full_unstemmed | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title_short | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy |
title_sort | survival outcome according to kras mutation status in newly diagnosed patients with stage iv non-small cell lung cancer treated with platinum doublet chemotherapy |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745798/ https://www.ncbi.nlm.nih.gov/pubmed/26471290 |
work_keys_str_mv | AT bradyannak survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT mcneilljonathand survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT judybrendan survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT baumljoshua survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT evanstraceyl survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT cohenrogerb survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT langercorey survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT vachanianil survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy AT aggarwalcharu survivaloutcomeaccordingtokrasmutationstatusinnewlydiagnosedpatientswithstageivnonsmallcelllungcancertreatedwithplatinumdoubletchemotherapy |